The Role of 68Ga-FAPI-04 PET/CT in Gastric and Pancreatic Cancers
Palabras clave
Abstracto
fechas
| Verificado por última vez: | 05/31/2020 |
| Primero enviado: | 06/13/2020 |
| Inscripción estimada enviada: | 06/18/2020 |
| Publicado por primera vez: | 06/21/2020 |
| Última actualización enviada: | 06/20/2020 |
| Última actualización publicada: | 06/22/2020 |
| Fecha de inicio real del estudio: | 06/22/2020 |
| Fecha estimada de finalización primaria: | 07/04/2020 |
| Fecha estimada de finalización del estudio: | 06/22/2021 |
Condición o enfermedad
Intervención / tratamiento
Radiation: gastric and pancreatic cancers
Fase
Grupos de brazos
| Brazo | Intervención / tratamiento |
|---|---|
| Experimental: gastric and pancreatic cancers The study population will include 25 patients with one of the following indications:
Exocrine Pancreatic cancer.
Gastric carcinoma, either with low-FDG uptake or known to be mucin-producing or signet-ring carcinoma.
The study population will include only patients treated in Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, and referred by their attending physicians, of whom are part of the hospital staff. | Radiation: gastric and pancreatic cancers Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days.
Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists.
Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression. |
Criterio de elegibilidad
| Edades elegibles para estudiar | 18 Years A 18 Years |
| Sexos elegibles para estudiar | All |
| Acepta voluntarios saludables | si |
| Criterios | Inclusion Criteria: The study population will include 25 patients with one of the following indications: 1. Exocrine Pancreatic cancer. 2. Gastric carcinoma, either with low-FDG uptake or known to be mucin-producing or signet-ring carcinoma. - The study population will include only patients treated in Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, and referred by their attending physicians, of whom are part of the hospital staff. Exclusion Criteria: - Age < 18 years. - Pregnant females. - Patients who are reluctant to undergo both FDG and FAPI PET scans. |
Salir
Medidas de resultado primarias
1. Patients who preformed 68Ga-FAPI-04 PSMA. [1 year]
2. Patients who preformed 68Ga-FAPI-04 PSMA and PET/CT FDG. [1 year]
3. Patients who preformed 68Ga-FAPI-04 PSMA and PET/MRI. [1 year]
